CalciMedica, Inc.

CalciMedica, Inc. announced changes to its Board of Directors. The Board increased its size from seven to eight directors and appointed Evgeny Zaytsev, M.D., Ph.D., as a Class I director, effective July 2, 2026. Dr. Zaytsev will receive an annual cash retainer of $40,000 and an option to purchase 20,000 shares of common stock. Concurrently, Fred Middleton informed the Board of his retirement, effective at the 2026 annual meeting of stockholders, after which the Board size will revert to seven directors.

CalciMedica, Inc. announced a private placement financing for up to approximately $49 million in gross proceeds, with an upfront amount of $15 million. The financing involves the sale of 18,673,429 units to new and existing investors, including management and board members. The company intends to use the proceeds to advance its pulmonary hypertension program, including a Phase 1b study for Auxora and IND clearance for CM5480. Additionally, the FDA has reviewed interim safety data for CalciMedica's Phase 2 KOURAGE trial for Auxora and provided no comments, allowing clinical development to continue.

CalciMedica, Inc. amended its loan and security agreement with Avenue Venture Opportunities Fund II, L.P., extending the interest-only period to September 30, 2027, and the maturity date to September 1, 2029, for its $10 million loan. The company agreed to increase the final payment fee by $200,000. Additionally, the lender's conversion option was expanded to $3 million, and an existing warrant's exercise price was reduced from $2.32 to $1.00, while a new warrant for 1 million shares at $1.00 was issued.

CalciMedica, Inc. reported a net income of $5.0 million for the three months ended March 31, 2026, a significant improvement from a net loss of $5.0 million in the prior year period. Despite this, the company maintains an accumulated deficit of $184.4 million and its management has raised substantial doubt about its ability to continue as a going concern, citing insufficient cash and cash equivalents to fund operations for the next year. The company plans to seek additional funding through various financing and collaboration agreements.

CalciMedica reported a net income of $5.0 million, or $0.30 diluted EPS, for Q1 2026, a significant improvement from a $5.0 million net loss in Q1 2025, primarily due to a $9.1 million increase in other income from fair value adjustments. The company continues to engage with the FDA regarding the pivotal program design for Auxora in acute pancreatitis (AP), with feedback expected in Q2 2026, following positive Phase 2b CARPO trial results published in eClinicalMedicine. Additionally, FDA feedback on Auxora's potential future development in acute kidney injury (AKI) is also anticipated in Q2 2026, and preclinical studies for CM5480 in pulmonary hypertension are advancing towards a 2027 IND submission.

CalciMedica, Inc. filed an Amendment No. 1 on Form 10-K/A to its Annual Report for the fiscal year ended December 31, 2025. This amendment provides the previously omitted information required by Part III of the original filing, covering directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, and principal accounting fees. The filing includes detailed compensation tables for named executive officers for 2025 and 2024, as well as information on equity awards and severance policies.